Biocoat, Inc. Names Steven Bell Chief Financial Officer

Bell to lead financial growth planning for leading biomaterial coatings company

News provided by

Jan 23, 2019, 08:00 ET

HORSHAM, Pa., Jan. 23, 2019 /PRNewswire/ -- Biocoat, Inc. announced today that Steven Bell has joined the company as Chief Financial Officer (CFO). Based in Horsham, PA, Biocoat develops and licenses biomaterial coatings for interventional medical devices that are custom engineered to meet specific clinical design parameters.

Steven Bell, Chief Financial Officer, Biocoat, Inc.

"It is a pleasure to add Steve to the Biocoat leadership team on a full-time basis. Steve has been working with Biocoat on a consultant basis for the past few months and played a key role in the recent merger between our organization and 1315 Capital, a prominent Philadelphia private-equity firm," said Jim Moran, President and CEO, Biocoat. "Steve's extensive knowledge in developing financial strategies, along with his global experience made it clear that he was a perfect match for the organization."

For the past several years, Steve has acted as a consultant providing outsourced CFO services for various middle market companies. Prior to launching his consulting practice, and for the majority of his professional career, Steve has held senior executive positions as a chief financial officer for middle market, public and privately held companies, including ReSearch Pharmaceutical Services, CareScience and The MRC Group.

"I was attracted to Biocoat by the vision of its leadership team and innovative growing business model. I am looking forward to being part of the continuing success of this organization," said Bell.

Steve received a Bachelor of Business Administration (BBA), Accounting from Temple University. He is on the Board and Treasurer of Shamrock Reins, a non-profit established to provide equine assisted activities and therapies. Steve is a member of the American and Pennsylvania Institutes of Certified Public Accountants, Pennsylvania Bio, Alliance of Merger & Acquisition Advisors, and The Greater Philadelphia Alliance for Capital and Technologies (PACT).

About Biocoat, Inc.
Biocoat, Inc. develops and licenses biomaterial coatings for medical devices that are custom engineered to meet specific clinical parameters. The company specializes in supplying lubricious hydrophilic coatings for medical devices to original equipment manufacturers and contract manufacturers. Biocoat is also able to provide coating services to aspiring medical device companies that require assistance with manufacturing. The company also sells diagnostic test kits in the reproductive market for use in male factor infertility.

To learn more about Biocoat visit www.biocoat.com, call 215-734-0888 or connect on LinkedIn and Twitter.

SOURCE Biocoat, Inc.